全球骨活检市场预测 (-2030)

在预测期内，全球骨活检市场规模预计将以 5.25% 的复合年增长率增长。 市场增长的驱动因素包括恶性骨肿瘤的流行以及人们对骨髓活检检测和治疗淋巴瘤和白血病的认识不断提高。

本报告研究和分析全球骨活检市场，提供市场动态、细分分析、区域分析、公司概况等。

内容

第 1 章执行摘要

第二章市场介绍

第三章研究方法论

第四章市场动态

• 概览
• 司机
• 约束因素
• 机会

第五章市场因素分析

• 价值链分析
  • 研发与设计
  • 製造业
  • 分销和销售
  • 售后审查
• 波特的五力模型
• COVID-19 的影响
  • 对需求的影响
  • 对供应链的影响

第 6 章全球骨活检市场：按类型

• 概览
• 穿刺活检
• 切开活检

第 7 章全球骨活检市场：按指南

• 概览
• 核磁共振指南
• CT 指南

第 8 章全球骨活检市场：按最终用户分类

• 概览
• 医院和诊所
• 手术中心
• 其他

第 9 章全球骨活检市场：按地区

• 概览
• 北美
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 韩国
  • 亚太其他地区
• 其他地区
  • 中东
  • 非洲
  • 拉丁美洲

第10章竞争格局

• 概览
• 竞争基准
• 全球骨活检市场的主要增长战略
• 全球骨活检市场发展数量的主要参与者
• 主要发展分析
• 主要发展和增长战略
• 主要公司的财务矩阵

第11章公司简介

• ARGON MEDICAL
• B. BRAUN MELSUNGEN AG
• BECTON, DICKINSON, AND COMPANY
• CARDINAL HEALTH
• MERMAID MEDICAL GROUP
• KIMAL PLC
• STRYKER
• COOK MEDICAL
• PRODUCTS/S OFFERED
• REMINGTON MEDICAL
• MERIT MEDICAL SYSTEMS

第12章 附录

Market Overview

The bone biopsy market is projected to register a CAGR of 5.25% during the gauge time frame. Bone biopsy utilizes a needle and imaging direction to wipe out a little example of bone for assessment under a magnifying lens. Bone biopsies might be utilized to approve the conclusion of a bone problem, inspect an irregularity, lay out the reason for torment or disease, or separate bone growths from different circumstances. Developing interest in insignificantly obtrusive methodology is fuelling the development of the worldwide bone biopsy market. An insignificantly obtrusive methodology is the utilization of various procedures to work with less harm to the patient's body. It has different advantages, for example, less employable and post-usable significant difficulties, less post-usable torment, abbreviated clinic stays, and quicker recuperation times.

The increase in the worldwide bone biopsy market is driven by the elements like the rising commonness of bone malignant growths and expanding acknowledgment of bone marrow biopsy for finding and the d treatment of lymphoma and leukemia illness. What's more, further developing medical services foundations across arising nations sets out to reward freedom for the market. Notwithstanding, severe administrative approaches are probably going to limit market development.

Market Segmentation

Based on Type, the global Bone Biopsy Market is bifurcated into Needle Biopsy and Open Biopsy. MRI-Guided and CT-Guided products make up the market's GUIDED category. For the identification of live tumors, lesions that cannot be seen by CT, and bone marrow lesions, a biopsy performed under MRI guidance is very helpful (after chemotherapy or radiation).

The End User segment is made up of hospitals and Clinics, Surgical Centres, and Others. Bone biopsy proceeds as a short-term technique in the clinic that typically takes under an hour and clinics are one of the primary contact focus and the most trustable choice for patients. The developing frequency and predominance of malignant growth, rising interest in negligibly obtrusive strategies, and enormous geriatric patient populace are driving the interest in the bone biopsy.

Regional Analysis

In North America, the bone biopsy market is credited to the rising predominance of bone problems like bone disease, osteoporosis osteomyelitis, and others. Additionally, the presence of good repayment approaches, advanced medical services foundation, and quick reception of cutting-edge clinical innovations in the region drive the regional market development during the gauge time frame.

Asia-Pacific is expected to enlist the most noteworthy development rate over the estimated period. This is because of the elements like further developing medical services framework, government drives, and the rising patient populace experiencing bone malignant growth, bone Contamination, osteoporosis, constant kidney infection, and other bone problems. For example, as indicated by the Global Osteoporosis Establishment, by

Major Players

The Key companies operating in a global Bone Biopsy Market are Argon Medical (US), Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US).

TABLE OF CONTENTS

LIST OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF BONE CANCER
  • 4.2.2 GROWING DEMAND FOR MINIMALLY INVASIVE PROCEDURES
  • 4.2.3 INCREASING ACCEPTANCE OF BONE MARROW BIOPSY FOR DIAGNOSIS AND TREATMENT OF LYMPHOMA AND LEUKEMIA DISEASE
• 4.3 RESTRAINTS
• 4.4 OPPORTUNITIES
  • 4.4.1 IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D AND DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES REVIEW
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF BUYERS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19
  • 5.3.1 IMPACT ON DEMAND
  • 5.3.2 IMPACT ON SUPPLY CHAIN

6 GLOBAL BONE BIOPSY MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 NEEDLE BIOPSY
• 6.3 OPEN BIOPSY

7 GLOBAL BONE BIOPSY MARKET, BY GUIDED

• 7.1 OVERVIEW
• 7.2 MRI-GUIDED
• 7.3 CT-GUIDED

8 GLOBAL BONE BIOPSY MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS AND CLINICS
• 8.3 SURGICAL CENTERS
• 8.4 OTHERS

9 GLOBAL BONE BIOPSY MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 JAPAN
  • 9.4.2 CHINA
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL BONE BIOPSY MARKET
• 10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BONE BIOPSY MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
  • 10.6.2 PARTNERSHIP/COLLABORATION
• 10.7 MAJOR PLAYERS FINANCIAL MATRIX
  • 10.7.1 SALES 2021
  • 10.7.2 R&D EXPENDITURE (USD MILLION), 2021
• 11.1 ARGON MEDICAL
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 B. BRAUN MELSUNGEN AG
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BECTON, DICKINSON, AND COMPANY
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 CARDINAL HEALTH
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 MERMAID MEDICAL GROUP
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 KIMAL PLC
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 STRYKER
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 COOK MEDICAL
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS/S OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 REMINGTON MEDICAL
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 MERIT MEDICAL SYSTEMS
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS

LIST OF TABLES

• TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
• TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
• TABLE 3 GLOBAL BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 4 GLOBAL BONE BIOPSY MARKET, FOR NEEDLE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5 GLOBAL BONE BIOPSY MARKET, FOR OPEN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6 GLOBAL BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 7 GLOBAL BONE BIOPSY MARKET, FOR MRI-GUIDED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8 GLOBAL BONE BIOPSY MARKET, FOR CT-GUIDED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9 GLOBAL BONE BIOPSY MARKET, BY END USER 2018-2030 (USD MILLION)
• TABLE 10 GLOBAL BONE BIOPSY MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11 GLOBAL BONE BIOPSY MARKET, FOR SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12 GLOBAL BONE BIOPSY MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13 GLOBAL: BONE BIOPSY MARKET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14 NORTH AMERICA: BONE BIOPSY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 15 NORTH AMERICA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 16 NORTH AMERICA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 17 NORTH AMERICA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18 US: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19 US: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 20 US : BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21 CANADA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22 CANADA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 23 CANADA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24 EUROPE: BONE BIOPSY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25 EUROPE: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26 EUROPE: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 27 EUROPE: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28 GERMANY: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29 GERMANY: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 30 GERMANY: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31 UK: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32 UK: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 33 UK: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34 FRANCE: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35 FRANCE: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 36 FRANCE: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37 ITALY: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38 ITALY: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 39 ITALY: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40 SPAIN: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41 SPAIN: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 42 SPAIN: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43 REST OF EUROPE: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44 REST OF EUROPE: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 45 REST OF EUROPE: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46 ASIA-PACIFIC: BONE BIOPSY MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47 ASIA-PACIFIC: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48 ASIA-PACIFIC: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 49 ASIA-PACIFIC: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50 JAPAN: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51 JAPAN: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 52 JAPAN: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53 CHINA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54 CHINA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 55 CHINA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56 INDIA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57 INDIA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 58 INDIA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59 AUSTRALIA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60 AUSTRALIA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 61 AUSTRALIA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62 SOUTH KOREA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63 SOUTH KOREA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 64 SOUTH KOREA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65 REST OF ASIA-PACIFIC: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66 REST OF ASIA-PACIFIC: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 67 REST OF ASIA-PACIFIC: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68 REST OF THE WORLD: BONE BIOPSY MARKET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 69 REST OF THE WORLD: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70 REST OF THE WORLD: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 71 REST OF THE WORLD: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72 MIDDLE EAST: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73 MIDDLE EAST: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 74 MIDDLE EAST: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75 AFRICA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76 AFRICA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 77 AFRICA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78 LATIN AMERICA: BONE BIOPSY MARKET, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79 LATIN AMERICA: BONE BIOPSY MARKET, BY GUIDED, 2018-2030 (USD MILLION)
• TABLE 80 LATIN AMERICA: BONE BIOPSY MARKET, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81 MAJOR PLAYERS IN THE GLOBAL BONE BIOPSY MARKET
• TABLE 82 MOST ACTIVE PLAYERS IN THE GLOBAL BONE BIOPSY MARKET
• TABLE 83 PRODUCT LAUNCH/PRODUCT APPROVAL
• TABLE 84 PARTNERSHIP/COLLABORATION
• TABLE 85 ARGON MEDICAL: PRODUCTS OFFERED
• TABLE 86 ARGON MEDICAL: KEY DEVELOPMENTS
• TABLE 87 B. BRAUN MELSUNGEN AG: PRODUCTS OFFERED
• TABLE 88 BECTON, DICKINSON, AND COMPANY: PRODUCTS OFFERED
• TABLE 89 CARDINAL HEALTH: PRODUCTS OFFERED
• TABLE 90 MERMAID MEDICAL GROUP: PRODUCTS OFFERED
• TABLE 91 KIMAL PLC: PRODUCTS OFFERED
• TABLE 92 STRYKER: PRODUCTS OFFERED
• TABLE 93 COOK: PRODUCTS/ OFFERED
• TABLE 94 REMINGTON MEDICAL: PRODUCTSOFFERED
• TABLE 95 MERIT MEDICAL SYSTEMS: PRODUCTS OFFERED
• TABLE 96 MERIT MEDICAL SYSTEMS: KEY DEVELOPMENTS  

LIST OF FIGURES

• FIGURE 1 MARKET SYNOPSIS
• FIGURE 2 GLOBAL BONE BIOPSY MARKET
• FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
• FIGURE 4 MARKET DYNAMICS: GLOBAL BONE BIOPSY MARKET
• FIGURE 5 DRIVERS: IMPACT ANALYSIS
• FIGURE 6 RESTRAINT: IMPACT ANALYSIS
• FIGURE 7 VALUE CHAIN: GLOBAL BONE BIOPSY MARKET
• FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BONE BIOPSY MARKET
• FIGURE 9 GLOBAL BONE BIOPSY MARKET, BY TYPE, 2021 & 2030 (USD MILLION)
• FIGURE 10 GLOBAL BONE BIOPSY MARKET SHARE, BY TYPE, 2021 (%)
• FIGURE 11 GLOBAL BONE BIOPSY MARKET, BY GUIDED, 2021 & 2030 (USD MILLION)
• FIGURE 12 GLOBAL BONE BIOPSY MARKET SHARE, BY GUIDED, 2021 (%)
• FIGURE 13 GLOBAL BONE BIOPSY MARKET, BY END USER, 2021 & 2030 (USD MILLION)
• FIGURE 14 GLOBAL BONE BIOPSY MARKET SHARE, BY END USER, 2021 (%)
• FIGURE 15 GLOBAL: BONE BIOPSY MARKET, BY REGION 2021 & 2030 (USD MILLION)
• FIGURE 16 GLOBAL: BONE BIOPSY MARKET SHARE (%), BY REGION, 2021
• FIGURE 17 NORTH AMERICA: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
• FIGURE 18 EUROPE: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
• FIGURE 19 ASIA-PACIFIC: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
• FIGURE 20 REST OF THE WORLD: BONE BIOPSY MARKET SHARE (%), BY COUNTRY, 2021
• FIGURE 21 BENCHMARKING OF MAJOR COMPETITORS
• FIGURE 22 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL BONE BIOPSY MARKET
• FIGURE 23 GLOBAL BONE BIOPSY MARKET: COMPETITIVE LANDSCAPE
• FIGURE 24 SALES 2021
• FIGURE 25 R&D EXPENDITURE (USD MILLION), 2021
• FIGURE 26 ARGON MEDICAL: SWOT ANALYSIS
• FIGURE 27 B. BRAUN MELSUNGEN AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 28 B. BRAUN MELSUNGEN AG: SWOT ANALYSIS
• FIGURE 29 BECTON, DICKINSON, AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 30 BECTON, DICKINSON, AND COMPANY: SWOT ANALYSIS
• FIGURE 31 CARDINAL HEALTH: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 32 CARDINAL HEALTH, INC.: SWOT ANALYSIS
• FIGURE 33 STRYKER: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 34 STRYKER: SWOT ANALYSIS
• FIGURE 35 COOK: SWOT ANALYSIS
• FIGURE 36 MERIT MEDICAL SYSTEMS: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 MERIT MEDICAL SYSTEMS: SWOT ANALYSIS